M&A · Healthcare · Pharmaceutical Preparations
Scancell Holdings plc to acquire Neuphoria Therapeutics Inc.
Announced Jul 23, 2026 · Closed Jul 24, 2026
Deal value—
Premium—To unaffected price
EV / Adj. EBITDA—
ConsiderationAll stock
Transaction
- Acquirer
- Scancell Holdings plc (SCNLD)
- Target
- Neuphoria Therapeutics Inc. (NEUP)
- Buyer type
- Strategic
- Offer price per share
- —
- Enterprise value
- —
- Status
- Closed Jul 24, 2026
Deal protections
- Break fee (target pays)
- —
- Reverse fee (buyer pays)
- —
- Go-shop
- No-shop
- Financing
- —
Advisors
- To the acquirer
- Leerink Partners
- To the target
- H.C. Wainwright
Sector context · Healthcare
- Comparable deals
- 103 in the prior 24 months
- Premium
- Sector median 47.0%
- EV / Adj. EBITDA
- Sector median 10.9x
- Break fee
- Sector median 3.5%
Timeline
- AnnouncedJul 23, 2026
- ClosedJul 24, 2026